Brief: Valbiotis Launches Late Stage Development Phase Of Totum-63

Valbiotis SA

02/04/2020 06:59

April 2 (Reuters) - VALBIOTIS SA  ALVAL.PA :
    * ANNOUNCES TODAY, THAT AS PART OF ITS GLOBAL PARTNERSHIP
WITH
NESTLÉ HEALTH SCIENCE, IT IS LAUNCHING THE PIVOTAL LATE STAGE
DEVELOPMENT PHASE OF TOTUM-63
    * THIS INTERNATIONAL TRIAL WILL INCLUDE 600 PARTICIPANTS AND
SHOULD BE LAUNCHED BEFORE MID-2020
    * ITS FIRST OBJECTIVE IS TO CONFIRM POSITIVE RESULTS OF
PHASE II
CLINICAL TRIAL ON FASTING BLOOD SUGAR LEVELS, A WELL-ESTABLISHED
RISK FACTOR FOR DEVELOPING TYPE 2 DIABETES, TO OBTAIN STRONG
HEALTH CLAIMS
    * THIS LAST PIVOTAL TRIAL (REVERSE-IT), HAS BEEN DESIGNED
JOINTLY
WITH NESTLÉ HEALTH SCIENCE'S TEAMS AND WILL BE ENTIRELY FUNDED
BY PARTNERSHIP AGREEMENT

Source text for Eikon:  ID:nBw51pvxxa 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))